Table 2.
Sequencea |
||
Oligonucleotide | Forward | Reverse |
FOXC1 site | GATCCAAAGTAAATAAACAACAGA | GATCTCTGTTGTTTATTTACTTTG |
Variant: | ||
1 | GATCCAAACTAAATAAACAACAGA | GATCTCTGTTGTTTATTTAGTTTG |
2 | GATCCAAAGAAAATAAACAACAGA | GATCTCTGTTGTTTATTTTCTTTG |
3 | GATCCAAAGTTAATAAACAACAGA | GATCTCTGTTGTTTATTAACTTTG |
4 | GATCCAAAGTATATAAACAACAGA | GATCTCTGTTGTTTATATACTTTG |
5 | GATCCAAAGTAATTAAACAACAGA | GATCTCTGTTGTTTAATTACTTTG |
6 | GATCCAAAGTAAAAAAACAACAGA | GATCTCTGTTGTTTTTTTACTTTG |
7 | GATCCAAAGTAAATTAACAACAGA | GATCTCTGTTGTTAATTTACTTTG |
8 | GATCCAAAGTAAATATACAACAGA | GATCTCTGTTGTATATTTACTTTG |
9 | GATCCAAAGTAAATAATCAACAGA | GATCTCTGTTGATTATTTACTTTG |
The 9-bp core sequence of the in vitro–derived FOXC1 site (Pierrou et al. 1994) and of the variants is underlined; the converted base in each oligonucleotide is shown in boldface italics. Purines were converted to pyrimidines with an equivalent number of hydrogen bonds, and pyrimidines were converted to purines with an equivalent number of hydrogen bonds.